Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kos Niaspan/Simvastatin Combination NDA Planned For 2006

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Kos is targeting an NDA for its Niaspan/simvastatin combination product for 2006, following the completion of two pivotal trials in patients with mixed dyslipidemia.

You may also be interested in...

Obesity Market Could See Two Near-Term Entrants; Pfizer Says Combo Is Key

Obesity market could see two near-term entrants, Pfizer says. Sanofi-Aventis will submit Acomplia in early Q2 2005; Regeneron’s Axokine is in Phase III. Pfizer is looking at combination therapy for metabolic syndrome, including Caduet and atorvastatin/torcetrapib. Firms are focusing on cardiovascular benefits

Aradigm Inhaled Insulin Type 1 Diabetes Study Raises Efficacy Concern

Novo Nordisk and Aradigm may focus on type 2 diabetes only for their AERx iDMS inhaled insulin system NN1998 following disappointing glucose suppression results in a Phase III type 1 diabetes trial.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts